

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Condensed Balance Sheets (Reviewed, Not Audited)
Three Months Ended March 31, 2021 and 2020

Unit : NT\$ Thousands

Assets	<u>March 31, 20 21</u>		<u>December 31, 20 20</u>		<u>March 31, 20 20</u>		
	<u>A m o u n t</u>	<u>%</u>	<u>A m o u n t</u>	<u>%</u>	<u>A m o u n t</u>	<u>%</u>	
Current Assets							
1100	Cash and Cash Equivalents	\$ 1,131,968	9	\$ 1,034,239	8	\$ 863,381	7
1136	Amortised cost of a financial asset –						
	Current	-	-	400	-	-	-
1150	Notes Receivable	304,851	2	324,175	3	378,772	3
1160	Notes Receivable – Related Parties	136,585	1	114,913	1	155,244	1
1170	Accounts Receivable	1,589,458	13	1,671,811	14	1,740,601	15
1180	Other Receivables	39,491	-	55,237	-	45,427	1
1200	Other Receivables –Related Parties	87,754	1	85,266	1	37,433	-
1210	Other Receivable	187,240	2	188,447	2	191,632	2
130X	Inventories	2,393,113	19	2,402,224	19	2,127,670	18
1476	Other Financial Assets- Current	4,342	-	-	-	4,667	-
1479	Other Assets- Current	51,559	-	50,639	-	118,461	1
11XX	Total Current Assets	<u>5,926,361</u>	<u>47</u>	<u>5,927,351</u>	<u>48</u>	<u>5,663,288</u>	<u>48</u>
Non-Current assets							
1517	Financial assets measured at fair value through other comprehensive income –						
	Noncurrent	1,010,127	8	741,685	6	523,082	4
1550	Long-term Investments at Equity	1,023,264	8	963,485	8	950,374	8
1600	Property, Plant and Equipment	4,158,504	33	4,254,179	34	4,225,046	36
1755	Assets Appropriative Right	91,906	1	95,647	1	91,779	1
1760	Investment Property	60,189	-	-	-	-	-
1780	Intangible Assets	24,735	-	27,734	-	22,608	-
1840	Deferred Tax Assets	212,228	2	211,744	2	195,230	2
1900	Other Non-current Assets	137,745	1	135,089	1	149,306	1
15XX	Total Non-Current Assets	<u>6,718,698</u>	<u>53</u>	<u>6,429,563</u>	<u>52</u>	<u>6,157,425</u>	<u>52</u>
1XXX	Total Assets	<u>\$ 12,645,059</u>	<u>100</u>	<u>\$ 12,356,914</u>	<u>100</u>	<u>\$ 11,820,713</u>	<u>100</u>

(Continue)

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Condensed Balance Sheets (Reviewed, Not Audited)
Three Months Ended March 31, 2021 and 2020

Unit : NT\$ Thousands

Liabilities and Shareholders' Equity		<u>March 31, 20</u>	<u>2 1</u>	<u>December 31, 20</u>	<u>2 0</u>	<u>March 31, 20</u>	<u>2 0</u>
		<u>A m o u n t</u>	<u>%</u>	<u>A m o u n t</u>	<u>%</u>	<u>A m o u n t</u>	<u>%</u>
Current Liabilities							
2100	Short-term Borrowings	\$ 1,277,441	10	\$ 1,143,283	9	\$ 1,487,590	13
2110	Short-Term Notes and Bills Payable	230,000	2	210,000	2	67,480	1
2130	Contractual Liability – Current	30,252	-	72,091	-	20,873	-
2150	Notes Payable	22,846	-	-	-	23,336	-
2170	Accounts Payable	876,918	7	960,728	8	1,034,501	9
2200	Other Payables	521,526	4	717,857	6	453,682	4
2230	Current Income Tax Liabilities	88,889	1	74,225	1	62,406	-
2280	Lease Liabilities – Current	13,647	-	13,626	-	9,161	-
2320	Refund Liability – Current	21,000	-	21,000	-	21,000	-
2365	Other Current Liabilities	65,951	1	73,512	1	71,414	1
2399	Current Income Tax Liabilities	18,920	-	26,306	-	15,590	-
21XX	Total Non-Current Liabilities	<u>3,167,390</u>	<u>25</u>	<u>3,312,628</u>	<u>27</u>	<u>3,267,033</u>	<u>28</u>
Non-Current Liabilities							
2540	Long-term Borrowings	2,046,000	16	2,046,000	17	2,069,000	17
2570	Deferred Income Tax Liabilities	148,576	1	137,826	1	131,856	1
2580	Lease Liabilities – Uncurrent	61,386	1	64,775	-	65,148	1
2600	Other Non-Current Liabilities	151,741	1	168,826	1	162,361	1
25XX	Total Non-Current Liabilities	<u>2,407,703</u>	<u>19</u>	<u>2,417,427</u>	<u>19</u>	<u>2,428,365</u>	<u>20</u>
2XXX	Total Liabilities	<u>5,575,093</u>	<u>44</u>	<u>5,730,055</u>	<u>46</u>	<u>5,695,398</u>	<u>48</u>
Equity Attributable to Owners of Parent							
Share Capital							
3110	Ordinary Share	2,980,811	24	2,980,811	24	2,980,811	25
Capital Surplus							
3200	Capital Surplus	646,000	6	646,000	6	645,774	6
Retained Earnings							
3310	Legal Reserve	535,449	4	535,449	4	496,980	4
3320	Special Reserve	188,958	1	188,958	2	188,958	2
3350	Unappropriated Retained Earnings	2,253,699	18	2,042,582	17	1,718,244	14
3400	Other Interest	457,480	3	225,931	1	87,924	1
3500	Treasury Stock	(28,054)	-	(28,054)	-	(28,054)	-
31XX	Noncontrolling Interests	<u>7,034,343</u>	<u>56</u>	<u>6,591,677</u>	<u>54</u>	<u>6,090,637</u>	<u>52</u>
36XX	Total Shareholders' Equity	<u>35,623</u>	<u>-</u>	<u>35,182</u>	<u>-</u>	<u>34,678</u>	<u>-</u>
3XXX	Significant Contingent Liability & Unrealized Contractual Arrangement	<u>7,069,966</u>	<u>56</u>	<u>6,626,859</u>	<u>54</u>	<u>6,125,315</u>	<u>52</u>
3X2X	Noncontrolling Interests	<u>\$ 12,645,059</u>	<u>100</u>	<u>\$ 12,356,914</u>	<u>100</u>	<u>\$ 11,820,713</u>	<u>100</u>

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements Of Comprehensive Income(Reviewed, Not Audited)
Three months Ended March 31, 2021 and 2020

Unit : NT\$ Thousands
(EPS: NT Dollars)

Item	F o r t h e T h r e e		M o n t h s E n d e d	
	M a r c h 3 1 , 2 0 2 1		M a r c h 3 1 , 2 0 2 0	
	A m o u n t	%	A m o u n t	%
4000 Operating Revenue	\$ 1,993,117	100	\$ 2,086,166	100
5000 Operating Costs	(1,233,965)	(62)	(1,316,441)	(63)
5950 Gross Profit from Operations	<u>759,152</u>	<u>38</u>	<u>769,725</u>	<u>37</u>
Operating Expenses				
6100 Selling Expenses	(462,816)	(23)	(488,301)	(23)
6200 Administrative Expenses	(67,853)	(4)	(53,534)	(3)
6300 Research and Development Expenses	(97,355)	(5)	(105,512)	(5)
6450 Expected Credit Losses	(3,841)	-	534	-
6000 Total Operating Expenses	<u>(631,865)</u>	<u>(32)</u>	<u>(646,813)</u>	<u>(31)</u>
6900 Net Operating Income	<u>127,287</u>	<u>6</u>	<u>122,912</u>	<u>6</u>
Non- Operating Income and Expenses				
7100 Other Revenue	3,745	-	2,183	-
7010 Other Gains and Losses	8,172	-	11,464	1
7020 Finance Cost	(3,254)	-	5,834	-
7050 Non- Operating Income and Expenses	(9,966)	-	(11,695)	(1)
7060 Share of Profit or Loss of Associates & Joint Ventures Accounted for Using Equity Method)	<u>34,383</u>	<u>2</u>	<u>14,137</u>	<u>1</u>
7000 Total Non-Operating Income and Expenses	<u>33,080</u>	<u>2</u>	<u>21,923</u>	<u>1</u>
7900 Income Before Income Tax	160,367	8	144,835	7
7950 IncomeTax Expense	(31,308)	(2)	(31,431)	(2)
8200 Net Income	<u>\$ 129,059</u>	<u>6</u>	<u>\$ 113,404</u>	<u>5</u>

(Continue)

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements Of Comprehensive Income(Reviewed, Not Audited)
Three months Ended March 31, 2021 and 2020

Unit : NT\$ Thousands
(EPS: NT Dollars)

Item	F o r t h e T h r e e		M o n t h s E n d e d		
	M a r c h 3 1 , 2 0 2 1	%	M a r c h 3 1 , 2 0 2 0	%	
	A m o u n t		A m o u n t		
Other Comprehensive Income that will be Reclassified to Profit or Loss					
8316	Unrealised Gains (Losses) on Financial assets measured at fair value through other comprehensive income	322,351	16	85,363	4
8320	Share of Other Comprehensive Income (Loss) of Subsidiaries and Associates Accounted for Using Equity Method - Won't be Reclassified to Profit	-	-	-	-
8310	Comprehensive Income That Will be not Reclassified to Profit or Loss Components of Other Comprehensive Income That Will be Reclassified to Profit or Loss	322,351	16	85,363	4
Income Tax not Related to Components of Other Comprehensive Income					
8361	Exchange Differences on Translation of Foreign Financial Statements	(10,015)	-	(16,132)	-
8370	Share of Other Comprehensive Income (Loss) of Subsidiaries and Associates Accounted for Using Equity Method - Will be Reclassified to Profit	(291)	-	101	-
8399	Income Tax Relating to Components of Other Comprehensive Income	2,003	-	3,226	-
8360	Total Components of Other Comprehensive Income That Will be Reclassified to Profit or Loss	(8,303)	-	(12,805)	-
8300	Total Net Comprehensive Profit(Loss) After Tax	\$ 314,048	16	\$ 72,558	4
8500	Total Comprehensive Income	\$ 443,107	22	\$ 185,962	9
Net Income (Losses) Attributable to:					
8610	Shareholders of the Parent	\$ 128,618	6	\$ 111,615	5
8620	Noncontrolling Interests	\$ 441	-	\$ 1,789	-
Comprehensive Income Attributable to:					
8710	Shareholders of the Parent	\$ 442,666	22	\$ 184,173	9
8720	Noncontrolling Interests	\$ 441	-	\$ 1,789	-
9750	Earnings per Share	\$ 0.43		\$ 0.38	
9850	Diluted Earnings Per Share	\$ 0.43		\$ 0.38	

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statement of Changes in Equity
For the Year Ended March 31, 2021 and 2020

Unit : NT\$ Thousands

	Total Equity Attributable to Owners of Parent											Total Equity	
	Ordinary Share	Addition al Paid-In Capital	Treasury Stock Transacti ons	hange in ownership of a subsidiary	Legal Reserve	Special Reserve	Unappropri ated Retained Earnings	Other	Equity Interest	Unrealized Gains(Losse s) o n Availablefo r - s a l e Financial A s s e t s	Trea sury Stoc k		Total
January 1st to March 31, 2020													
Equity at Beginning Of Period	\$2,980,811	\$578,416	\$65,765	\$1,593	\$496,980	\$188,958	\$1,573,890	(\$97,944)	\$146,049	(\$28,054)	\$5,906,464	\$32,889	\$5,939,353
Consolidated Profit for The Year Ended March 31, 2020	-	-	-	-	-	-	111,615	-	-	-	111,615	1,789	113,404
Other Comprehensive Income	-	-	-	-	-	-	-	(12,805)	85,363	-	72,558	-	72,558
Total Consolidated Profit for The Year Ended March 31, 2020	-	-	-	-	-	-	111,615	(12,805)	85,363	-	184,173	1,789	185,962
Disposal of Financial assets measured at fair value through other comprehensive income	-	-	-	-	-	-	32,739	-	(32,739)	-	-	-	-
Balance, March 31, 2020	\$2,980,811	\$578,416	\$65,765	\$1,593	\$496,980	\$188,958	\$1,718,244	(\$110,749)	\$198,673	(\$28,054)	\$6,090,637	\$34,678	\$6,125,315
January 1st to March 31, 2021													
Equity at Beginning Of Period	\$2,980,811	\$578,416	\$66,240	\$1,344	\$535,449	\$188,958	\$2,042,582	(\$85,549)	\$311,480	(\$28,054)	\$6,591,677	\$35,182	\$6,626,859
Consolidated Profit for The Year Ended March 31, 2021	-	-	-	-	-	-	128,618	-	-	-	128,618	441	129,059
Other Comprehensive Income	-	-	-	-	-	-	-	(8,303)	322,351	-	314,048	-	314,048
Total Consolidated Profit for The Year Ended March 31, 2021	-	-	-	-	-	-	128,618	(8,303)	322,351	-	442,666	441	443,107
Disposal of Financial assets measured at fair value through other comprehensive income	-	-	-	-	-	-	82,499	-	(82,499)	-	-	-	-
Balance, March 31, 2021	\$2,980,811	\$578,416	\$66,240	\$1,344	\$535,449	\$188,958	\$2,253,699	(\$93,852)	\$551,332	(\$28,054)	\$7,034,343	\$35,623	\$7,069,966

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements Of Cash Flows(Reviewed, Not Audited)
Three months Ended March 31, 2021 and 2020

Unit : NT\$ Thousands

	<u>For the Three</u> <u>Months Ended</u> <u>March 31, 2021</u>	<u>For the Three</u> <u>Months Ended</u> <u>March 31, 2020</u>
<u>Cash Flows From (Used in) Operating Activities</u>		
Consolidated Profit (Loss) Before Tax	\$ 160,367	\$ 144,835
Depreciation expense	66,722	61,961
Amortized Expense	3,283	3,078
Expected Credit Losses	3,841	(534)
Decrease in Allowance for Sales Returns and Allowances	(10,936)	27,916
Interest Expense	9,966	11,695
Interest Revenue	(3,745)	(2,183)
Financial asset or financial liability at fair value through profit or loss	-	(113)
Share of gain (loss) of Associates and Joint Ventures Accounted for Using Equity Method	(34,383)	(14,137)
Gain on Disposal of Property, Plant and Equipment	136	(4,384)
Gain on Disposal of Financial asset or financial liability at fair value through profit or loss	-	65,174
Notes Receivable (Include Related Parties)	(2,348)	(58,610)
Accounts Receivable (Include Related Parties)	98,099	(118,829)
Other Receivable (Include Related Parties)	(1,281)	11,350
Inventories	6,811	45,799
Other Assets- Current	(920)	(720)
Contractual Liability—Current	(41,839)	(39,406)
Notes Payable	22,846	(4,837)
Accounts Payable	(79,839)	172,382
Other Payable	(178,544)	(92,673)
Refund Liability—Current	(7,561)	2,136
Other Current Liabilities	(7,951)	(10,591)
Other Non-Current Liabilities	(17,790)	(21,504)
Cash Inflow (Outflow) Generated from Operations	(15,066)	177,805
Interest Received	3,745	2,183
Interest Paid	(9,880)	(12,565)
Income Taxes Refund (Paid)	(4,023)	(3,050)
Net Cash Flows from (used in) Operating Activities	(25,224)	164,373

(Continue)

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements Of Cash Flows(Reviewed, Not Audited)
Three months Ended March 31, 2021 and 2020

Unit : NT\$ Thousands

	<u>For the Three Months Ended March 31, 2021</u>	<u>For the Three Months Ended March 31, 2020</u>
<u>Cash Flows From (Used in) Investing Activities</u>		
Decrease(Increase) in Receivables Financing	\$ -	\$ 9,000
Increase in Financial assets at amortized cost-Current	400	-
Decrease(Increase) in Pledged Deposit	(4,342)	-
Acquire of Financial assets measured at fair value through other comprehensive income	(87,149)	(37,907)
Disposal of Financial assets measured at fair value through other comprehensive income	131,906	56,995
Refund of Financial assets measured at fair value through other comprehensive income Reduction	9,000	-
Acquire of Long-term Investments at Equity	(25,689)	-
Purchase of Property, Plant and Equipment	(50,336)	(81,126)
Disposal of Property, Plant and Equipment	364	4,384
Purchase of Intangible Assets	(38)	(1,446)
Decrease(Increase) in Refundable Deposits	159	2,554
Decrease(Increase) in Other Non-current Assets	<u>1,746</u>	<u>2,078</u>
Net Cash Flows From (Used in) Investing Activities	<u>(23,979)</u>	<u>(45,468)</u>
<u>Cash flows from (used in) Financing Activities</u>		
Decrease(Increase) In Short-term Borrowings	134,158	207,719
Decrease(Increase) in Short-term Notes and Bills Payable	20,000	-
Lease Liability Principal Repayment	(3,373)	(2,567)
Proceeds from Long-term Borrowings	100,000	10,000
Repayment of Long-term Borrowings	(100,000)	(168,000)
Decrease(Increase) in Guarantee Deposits Received	<u>(58)</u>	<u>698</u>
Net cash FlowsFrom (Used in) Financing Activities	<u>150,727</u>	<u>47,850</u>
Effect of Exchange Rate Changes on Cash and Cash Equivalents	<u>(3,795)</u>	<u>(7,214)</u>
Net Increase (Decrease) In Cash and Cash Equivalents	97,729	159,541
Cash and Cash Equivalents at Beginning of Period	<u>1,034,239</u>	<u>703,840</u>
Cash and Cash Equivalents at End of Period	<u>\$ 1,131,968</u>	<u>\$ 863,381</u>